[{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Telethon Kids Institute","sponsor":"Child and Adolescent Health Service - Perth | Sao Paulo Clinical Hospital - SP | Rigshospitalet","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Telethon Kids Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Telethon Kids Institute \/ Child and Adolescent Health Service - Perth | Sao Paulo Clinical Hospital - SP | Rigshospitalet","highestDevelopmentStatusID":"11","companyTruncated":"Telethon Kids Institute \/ Child and Adolescent Health Service - Perth | Sao Paulo Clinical Hospital - SP | Rigshospitalet"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Alberta Health services | Institute of Health Economics, Canada","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Midodrine","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ Alberta Health services | Institute of Health Economics, Canada","highestDevelopmentStatusID":"11","companyTruncated":"University of Alberta \/ Alberta Health services | Institute of Health Economics, Canada"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Labo'Life","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"2LPAPI","moa":"Allergen cell","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Labo'Life","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Labo'Life \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Labo'Life \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"University of Houston | High Point University | Paratek Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wake Forest University Health Sciences \/ University of Houston | High Point University | Paratek Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ University of Houston | High Point University | Paratek Pharmaceuticals"},{"orgOrder":0,"company":"Laboratoires des M\u00e9dicaments St\u00e9riles","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Laboratoires des M\u00e9dicaments St\u00e9riles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"INQUIS Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ INQUIS Clinical Research","highestDevelopmentStatusID":"11","companyTruncated":"Nutricia Inc \/ INQUIS Clinical Research"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"INQUIS Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ INQUIS Clinical Research","highestDevelopmentStatusID":"11","companyTruncated":"Nutricia Inc \/ INQUIS Clinical Research"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Carbohydrate","year":"2024","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nabilone","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Megalabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megalabs \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Megalabs \/ Undisclosed"},{"orgOrder":0,"company":"Solventum","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Solventum","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solventum \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"Solventum \/ 3M Company"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molnlycke Health Care AB \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Molnlycke Health Care AB \/ Undisclosed"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"BioScience Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molnlycke Health Care AB \/ BioScience Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Molnlycke Health Care AB \/ BioScience Laboratories"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"BioScience Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molnlycke Health Care AB \/ BioScience Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Molnlycke Health Care AB \/ BioScience Laboratories"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ Amgen Inc"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plerixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Silverstein Eye Centers","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Adrenergic-alpha-1 receptor||Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Silverstein Eye Centers","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Silverstein Eye Centers \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Silverstein Eye Centers \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Asan Medical Center","sponsor":"REDNVIA","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asan Medical Center \/ REDNVIA","highestDevelopmentStatusID":"11","companyTruncated":"Asan Medical Center \/ REDNVIA"},{"orgOrder":0,"company":"University of Seville","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Epithelial cell adhesion molecule","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of Seville","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"University of Seville \/ Alcon Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Seville \/ Alcon Inc"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University Medical Center \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Vanderbilt University Medical Center \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Linical","sponsor":"Asan Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Linical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linical \/ Asan Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"Linical \/ Asan Medical Center"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Edward Geissler","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Edward Geissler","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Edward Geissler \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"Edward Geissler \/ Chiesi Group"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Diphtheria Antitoxin","moa":"fluoroquinolone derivatives","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Tosilate","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Tosilate","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Remimazolam Tosilate","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Tosilate","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Tosilate","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Remimazolam Tosilate","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"UConn Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UConn Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UConn Health \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ethanol","moa":"Gamma-aminobutyric acid receptor subunit alpha-1; Glutamate receptor ionotropic, NMDA 3A; Glycine receptor subunit alpha-1; Glycine receptor subunit alpha-2; Voltage-dependent L-type calcium channel subunit beta-1; 5-hydroxytryptamine receptor 3A; Gamma-aminobutyric acid receptor subunit alpha-2; Neuronal acetylcholine receptor subunit alpha-10; Voltage-dependent L-type calcium channel subunit alpha-1C; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-4; Gamma-aminobutyric acid receptor subunit alpha-3; Glutamate receptor 1; Voltage-dependent calcium channel gamma-1 subunit; Neuronal acetylcholine receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-6; Glutamate receptor 2; Glutamate receptor 4; Glutamate receptor 3; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2; G protein-activated inward rectifier potassium channel 1; G protein-activated inward rectifier potassium cha","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Foam","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ethanol","moa":"Gamma-aminobutyric acid receptor subunit alpha-1; Glutamate receptor ionotropic, NMDA 3A; Glycine receptor subunit alpha-1; Glycine receptor subunit alpha-2; Voltage-dependent L-type calcium channel subunit beta-1; 5-hydroxytryptamine receptor 3A; Gamma-aminobutyric acid receptor subunit alpha-2; Neuronal acetylcholine receptor subunit alpha-10; Voltage-dependent L-type calcium channel subunit alpha-1C; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-4; Gamma-aminobutyric acid receptor subunit alpha-3; Glutamate receptor 1; Voltage-dependent calcium channel gamma-1 subunit; Neuronal acetylcholine receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-6; Glutamate receptor 2; Glutamate receptor 4; Glutamate receptor 3; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2; G protein-activated inward rectifier potassium channel 1; G protein-activated inward rectifier potassium cha","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Foam","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Genome British Columbia | Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"University of British Columbia \/ Genome British Columbia | Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"University of British Columbia \/ Genome British Columbia | Johnson & Johnson"},{"orgOrder":0,"company":"IWK Health Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"IWK Health Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IWK Health Centre \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"IWK Health Centre \/ Undisclosed"},{"orgOrder":0,"company":"Vance Thompson Vision","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Vance Thompson Vision","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"Vance Thompson Vision \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Vance Thompson Vision \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Central Military Healthcare - Oral and Maxillofacial Surgery Department","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Central Military Healthcare - Oral and Maxillofacial Surgery Department","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Central Military Healthcare - Oral and Maxillofacial Surgery Department \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Central Military Healthcare - Oral and Maxillofacial Surgery Department \/ Undisclosed"},{"orgOrder":0,"company":"Patrick R. Oellers, MD","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Patrick R. Oellers, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"Patrick R. Oellers, MD \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Patrick R. Oellers, MD \/ Ocular Therapeutix"},{"orgOrder":0,"company":"AXIS Spine Center- a division of Northwest Specialty Hospital","sponsor":"Idaho Panhandle Health District","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AXIS Spine Center- a division of Northwest Specialty Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AXIS Spine Center- a division of Northwest Specialty Hospital \/ Idaho Panhandle Health District","highestDevelopmentStatusID":"11","companyTruncated":"AXIS Spine Center- a division of Northwest Specialty Hospital \/ Idaho Panhandle Health District"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Elagolix Sodium","moa":"Gonadotropin-releasing hormone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ AbbVie Inc"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Hanall Biopharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hanall Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier Annecy Genevois","sponsor":"Sanofi | Euraxi Pharma | Hospices Civils de Lyon | INSERM | Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Centre Hospitalier Annecy Genevois","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Annecy Genevois \/ Sanofi | Euraxi Pharma | Hospices Civils de Lyon | INSERM | Eurofins CDMO","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier Annecy Genevois \/ Sanofi | Euraxi Pharma | Hospices Civils de Lyon | INSERM | Eurofins CDMO"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Smofkabiven Extra Nitrogen","moa":"Homeostasis","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oil","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Tecnoquimicas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"COLOMBIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Tecnoquimicas","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tecnoquimicas \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Tecnoquimicas \/ Undisclosed"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Botswana Harvard AIDS Institute Partnership | Gansu Provincial Maternal and Child Health Care Hospital | ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beth Israel Deaconess Medical Center \/ Botswana Harvard AIDS Institute Partnership | Gansu Provincial Maternal and Child Health Care Hospital | ViiV Healthcare","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Botswana Harvard AIDS Institute Partnership | Gansu Provincial Maternal and Child Health Care Hospital | ViiV Healthcare"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Darunavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Darunavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Darunavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rilpivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Taichung Veterans General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Yung Shin Pharm Industrial \/ Taichung Veterans General Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Taichung Veterans General Hospital"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Fluoride","moa":"Hydroxyapatite","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Paste","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Universidad San Francisco de Quito","sponsor":"Universidad Tecnol\u00f3gica Equinoccial | Biocodex","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ECUADOR","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Saccharomyces Boulardii","moa":"Immune","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Universidad San Francisco de Quito","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad San Francisco de Quito \/ Universidad Tecnol\u00f3gica Equinoccial | Biocodex","highestDevelopmentStatusID":"11","companyTruncated":"Universidad San Francisco de Quito \/ Universidad Tecnol\u00f3gica Equinoccial | Biocodex"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mycophenolic Acid","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mizoribine","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH) | GMP synthase [glutamine-hydrolyzing]","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lee Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mizoribine","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH) | GMP synthase [glutamine-hydrolyzing]","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lee Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Acarbose","moa":"Maltase-glucoamylase | Pancreatic alpha-amylase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AgelessRx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AgelessRx \/ Undisclosed"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Systane Complete","moa":"Lipid layer","graph1":"Undisclosed","graph2":"Phase IV","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ Alcon Inc","highestDevelopmentStatusID":"11","companyTruncated":"National Taiwan University Hospital \/ Alcon Inc"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cosette Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Cosette Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"AFP Innovation Fund","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ AFP Innovation Fund","highestDevelopmentStatusID":"11","companyTruncated":"Unity Health Toronto \/ AFP Innovation Fund"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Merck & Co"},{"orgOrder":0,"company":"AustarPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oseltamivir Phosphate","moa":"Neuraminidase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AustarPharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AustarPharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AustarPharma \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Aarhus University Hospital","sponsor":"Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Aarhus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aarhus University Hospital \/ Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark","highestDevelopmentStatusID":"11","companyTruncated":"Aarhus University Hospital \/ Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark"},{"orgOrder":0,"company":"VA Sierra Nevada Health Care System","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Undisclosed","graph2":"Phase IV","graph3":"VA Sierra Nevada Health Care System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Sierra Nevada Health Care System \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"VA Sierra Nevada Health Care System \/ Merck & Co"},{"orgOrder":0,"company":"Duke University","sponsor":"Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Inclisiran Sodium","moa":"PCSK9 mRNA","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York","highestDevelopmentStatusID":"11","companyTruncated":"Duke University \/ Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Belgium Health Care Knowledge Centre | University Ghent","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Belgium Health Care Knowledge Centre | University Ghent","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Ghent \/ Belgium Health Care Knowledge Centre | University Ghent"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Gencor Pacific Limited","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Oleoylethanolamide","moa":"Peroxisome proliferator-activated receptor alpha; G-protein coupled receptor 55; Glucose-dependent insulinotropic receptor; Cannabinoid receptor 1","graph1":"Undisclosed","graph2":"Phase IV","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RDC Clinical \/ Gencor Pacific Limited","highestDevelopmentStatusID":"11","companyTruncated":"RDC Clinical \/ Gencor Pacific Limited"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Carbohydrate","year":"2024","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Maribavir","moa":"Phosphotransferase pUL97 | Serine\/threonine-protein kinase BGLF4","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of South Carolina \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Medical University of South Carolina \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Total Definer Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Total Definer Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Total Definer Research Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Total Definer Research Group \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Undisclosed","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Kim Young Sung","sponsor":"Korea University Guro Hospital | Chung-Ang University Gwangmyeong Hospital | HK inno.N | Gansu Wuwei Tumor Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Kim Young Sung","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kim Young Sung \/ Korea University Guro Hospital | Chung-Ang University Gwangmyeong Hospital | HK inno.N | Gansu Wuwei Tumor Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Kim Young Sung \/ Korea University Guro Hospital | Chung-Ang University Gwangmyeong Hospital | HK inno.N | Gansu Wuwei Tumor Hospital"},{"orgOrder":0,"company":"Ginefiv","sponsor":"Theramex","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Medroxyprogesterone Acetate","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Ginefiv","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginefiv \/ Theramex","highestDevelopmentStatusID":"11","companyTruncated":"Ginefiv \/ Theramex"},{"orgOrder":0,"company":"Gynuity Health Projects","sponsor":"KIST Medical College | Center for Research on Environment, Health and Population Activities | Bharatpur Eye Hospital | Lumbini Provincial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Progesterone receptor | Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Gynuity Health Projects","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gynuity Health Projects \/ KIST Medical College | Center for Research on Environment, Health and Population Activities | Bharatpur Eye Hospital | Lumbini Provincial Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Gynuity Health Projects \/ KIST Medical College | Center for Research on Environment, Health and Population Activities | Bharatpur Eye Hospital | Lumbini Provincial Hospital"},{"orgOrder":0,"company":"Gynuity Health Projects","sponsor":"Society of Family Planning","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Progesterone receptor | Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Gynuity Health Projects","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gynuity Health Projects \/ Society of Family Planning","highestDevelopmentStatusID":"11","companyTruncated":"Gynuity Health Projects \/ Society of Family Planning"},{"orgOrder":0,"company":"Taoyuan General Hospital","sponsor":"Medigen Vaccine Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MVC-COV1901","moa":"SARS-CoV-2 S","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Taoyuan General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taoyuan General Hospital \/ Medigen Vaccine Biologics","highestDevelopmentStatusID":"11","companyTruncated":"Taoyuan General Hospital \/ Medigen Vaccine Biologics"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Physician Services Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Haloperidol","moa":"Serotonin 2a (5-HT2a) receptor | D2-like dopamine receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Physician Services Incorporated","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Addiction and Mental Health \/ Physician Services Incorporated"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Toludesvenlafaxine HCl","moa":"Serotonin\/norepinephrine reuptake","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VI-0521","moa":"SGLT1\/SGLT2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Women\u2019s Hospital, Zhejiang University School of Medicine","sponsor":"Beijing Obstetrics and Gynecology Hospital | International Peace Maternity and Child Health Hospital | Nanjing Medical University | Anhui Women and Children's Medical Center | Jiaxing Maternity and Child Health Care Hospital | Gansu Maternal and Child Hea","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Chloroprocaine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Women\u2019s Hospital, Zhejiang University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Women\u2019s Hospital, Zhejiang University School of Medicine \/ Beijing Obstetrics and Gynecology Hospital | International Peace Maternity and Child Health Hospital | Nanjing Medical University | Anhui Women and Children's Medical Center | Jiaxing Maternity and Child Health Care Hospital | Gansu Maternal and Child Hea","highestDevelopmentStatusID":"11","companyTruncated":"Women\u2019s Hospital, Zhejiang University School of Medicine \/ Beijing Obstetrics and Gynecology Hospital | International Peace Maternity and Child Health Hospital | Nanjing Medical University | Anhui Women and Children's Medical Center | Jiaxing Maternity and Child Health Care Hospital | Gansu Maternal and Child Hea"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Diego \/ Pacira BioSciences"},{"orgOrder":0,"company":"MediSys Health Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"MediSys Health Network","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MediSys Health Network \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"MediSys Health Network \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Johnny K. Lee","sponsor":"Endeavor Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Johnny K. Lee","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnny K. Lee \/ Endeavor Health","highestDevelopmentStatusID":"11","companyTruncated":"Johnny K. Lee \/ Endeavor Health"},{"orgOrder":0,"company":"Norton Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Norton Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norton Healthcare \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Norton Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"AgelessRx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AgelessRx \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1273","moa":"Spike glycoprotein","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tecnoquimicas","sponsor":"DominguezLab","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"COLOMBIA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Tecnoquimicas","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tecnoquimicas \/ DominguezLab","highestDevelopmentStatusID":"11","companyTruncated":"Tecnoquimicas \/ DominguezLab"},{"orgOrder":0,"company":"Emirates Health Services","sponsor":"University of Sharjah","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.A.E","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Emirates Health Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emirates Health Services \/ University of Sharjah","highestDevelopmentStatusID":"11","companyTruncated":"Emirates Health Services \/ University of Sharjah"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"CareDx","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Undisclosed","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ CareDx","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ CareDx"},{"orgOrder":0,"company":"National Liver Institute, Egypt","sponsor":"Future Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"National Liver Institute, Egypt","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Liver Institute, Egypt \/ Future Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"National Liver Institute, Egypt \/ Future Pharmaceutical Industries"},{"orgOrder":0,"company":"Laboratorio Elea Phoenix","sponsor":"Carlos R. Rojo | University of Buenos Aires","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ARGENTINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Laboratorio Elea Phoenix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorio Elea Phoenix \/ Carlos R. Rojo | University of Buenos Aires","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorio Elea Phoenix \/ Carlos R. Rojo | University of Buenos Aires"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MEXICO","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Sophia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Sophia \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MEXICO","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Manzanilla Sophia","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Sophia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Sophia \/ Undisclosed"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Acetylsalicilic Acid","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PLX Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PLX Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Acetylsalicilic Acid","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PLX Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PLX Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Farzanah Laher","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Adacel","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Farzanah Laher","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Farzanah Laher \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Farzanah Laher \/ Sanofi"},{"orgOrder":0,"company":"Qualitas Health","sponsor":"Arizona State University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Almegapl","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Qualitas Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualitas Health \/ Arizona State University","highestDevelopmentStatusID":"11","companyTruncated":"Qualitas Health \/ Arizona State University"},{"orgOrder":0,"company":"Cl\u00ednica de Gastroenterologia","sponsor":"Nestle Health Sciences SA | Angelini Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Apricot","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Cl\u00ednica de Gastroenterologia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cl\u00ednica de Gastroenterologia \/ Nestle Health Sciences SA | Angelini Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Cl\u00ednica de Gastroenterologia \/ Nestle Health Sciences SA | Angelini Pharma"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Aquacelle Fish Oil Triglyceride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"University of Cadiz","sponsor":"Vegenat Healthcare | Instituto de investigaci\u00f3n e innovaci\u00f3n biom\u00e9dica de C\u00e1diz","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"At\u00e9mpero","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of Cadiz","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Cadiz \/ Vegenat Healthcare | Instituto de investigaci\u00f3n e innovaci\u00f3n biom\u00e9dica de C\u00e1diz","highestDevelopmentStatusID":"11","companyTruncated":"University of Cadiz \/ Vegenat Healthcare | Instituto de investigaci\u00f3n e innovaci\u00f3n biom\u00e9dica de C\u00e1diz"},{"orgOrder":0,"company":"Bandim Health Project","sponsor":"University of Southern Denmark | Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GUINEA-BISSAU","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bandim Health Project \/ University of Southern Denmark | Radboud University Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"Bandim Health Project \/ University of Southern Denmark | Radboud University Medical Center"},{"orgOrder":0,"company":"Bandim Health Project","sponsor":"University of Southern Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GUINEA-BISSAU","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG-Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bandim Health Project \/ University of Southern Denmark","highestDevelopmentStatusID":"11","companyTruncated":"Bandim Health Project \/ University of Southern Denmark"},{"orgOrder":0,"company":"Bandim Health Project","sponsor":"University of Southern Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GUINEA-BISSAU","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG-Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bandim Health Project \/ University of Southern Denmark","highestDevelopmentStatusID":"11","companyTruncated":"Bandim Health Project \/ University of Southern Denmark"},{"orgOrder":0,"company":"Bandim Health Project","sponsor":"University of Southern Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GUINEA-BISSAU","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BCG-Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bandim Health Project \/ University of Southern Denmark","highestDevelopmentStatusID":"11","companyTruncated":"Bandim Health Project \/ University of Southern Denmark"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BLI800","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"Main Line Center for Laser Surgery","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Main Line Center for Laser Surgery","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Main Line Center for Laser Surgery \/ Merz Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Main Line Center for Laser Surgery \/ Merz Therapeutics"},{"orgOrder":0,"company":"Struk Tetiana","sponsor":"Bionorica SE","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Chaste Berry Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Struk Tetiana","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Struk Tetiana \/ Bionorica SE","highestDevelopmentStatusID":"11","companyTruncated":"Struk Tetiana \/ Bionorica SE"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Cpg-Adjuvanted HBV Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Zhejiang Provincial CDC","sponsor":"China National Biotec Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"BK1301","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Zhejiang Provincial CDC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Provincial CDC \/ China National Biotec Group","highestDevelopmentStatusID":"11","companyTruncated":"Zhejiang Provincial CDC \/ China National Biotec Group"},{"orgOrder":0,"company":"Zhejiang Provincial CDC","sponsor":"China National Biotec Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"BK1301","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Zhejiang Provincial CDC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Provincial CDC \/ China National Biotec Group","highestDevelopmentStatusID":"11","companyTruncated":"Zhejiang Provincial CDC \/ China National Biotec Group"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DTap, Inactivated Poliovirus, Haemophilus B Conjugate and Hepatitis B Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Emergen-C Core","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Enterovirus 71 Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Changchun Institute of Biological Products Co., Ltd. | Shaanxi Provincial Center for Disease Control and Prevention | Mianxian CDC | Yangxian Center for Disease Control and Prevention | Peking University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepatitis A Live Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China National Biotec Group \/ Changchun Institute of Biological Products Co., Ltd. | Shaanxi Provincial Center for Disease Control and Prevention | Mianxian CDC | Yangxian Center for Disease Control and Prevention | Peking University","highestDevelopmentStatusID":"11","companyTruncated":"China National Biotec Group \/ Changchun Institute of Biological Products Co., Ltd. | Shaanxi Provincial Center for Disease Control and Prevention | Mianxian CDC | Yangxian Center for Disease Control and Prevention | Peking University"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Huazhi Rougan","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Granules","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen Innovax Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Xiamen Innovax Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Innovax Biotech \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xiamen Innovax Biotech \/ Undisclosed"},{"orgOrder":0,"company":"First Affiliated Hospital, Sun Yat-Sen University","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"First Affiliated Hospital, Sun Yat-Sen University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"First Affiliated Hospital, Sun Yat-Sen University \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"First Affiliated Hospital, Sun Yat-Sen University \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Sanofi"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Listerine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Listerine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Arafarma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Manosar","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Arafarma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arafarma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Arafarma \/ Undisclosed"},{"orgOrder":0,"company":"Bandim Health Project","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GUINEA-BISSAU","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Measles Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bandim Health Project \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bandim Health Project \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Institute of Biological Products","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Measles, Mumps And Rubella Vaccine, Live","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Shanghai Institute of Biological Products","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Institute of Biological Products \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Institute of Biological Products \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Meningococcal Group B Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"ClinOhio Research Services, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Metaxalone","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Primus Pharmaceutical \/ ClinOhio Research Services, LLC","highestDevelopmentStatusID":"11","companyTruncated":"Primus Pharmaceutical \/ ClinOhio Research Services, LLC"},{"orgOrder":0,"company":"China-Japan Friendship Hospital","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methylcholine Chloroacetate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"China-Japan Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China-Japan Friendship Hospital \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"11","companyTruncated":"China-Japan Friendship Hospital \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"Samuel Fortin","sponsor":"Institut de recherche clinique du littoral","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Monoglyceride Eicosapentaenoic Acid","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Samuel Fortin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samuel Fortin \/ Institut de recherche clinique du littoral","highestDevelopmentStatusID":"11","companyTruncated":"Samuel Fortin \/ Institut de recherche clinique du littoral"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Omega 1035DS","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"Austin Institute for Clinical Research","sponsor":"SkinCeuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Phyto A","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Austin Institute for Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Austin Institute for Clinical Research \/ SkinCeuticals","highestDevelopmentStatusID":"11","companyTruncated":"Austin Institute for Clinical Research \/ SkinCeuticals"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Shanghai Municipal Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal 23-valent Polysaccharide Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Serum","sponsorNew":"China National Biotec Group \/ Shanghai Municipal Center for Disease Control and Prevention","highestDevelopmentStatusID":"11","companyTruncated":"China National Biotec Group \/ Shanghai Municipal Center for Disease Control and Prevention"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Sichuan Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal 23-valent Polysaccharide Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Serum","sponsorNew":"China National Biotec Group \/ Sichuan Center for Disease Control and Prevention","highestDevelopmentStatusID":"11","companyTruncated":"China National Biotec Group \/ Sichuan Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Bandim Health Project","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GUINEA-BISSAU","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Polio Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bandim Health Project \/ Radboud University Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"Bandim Health Project \/ Radboud University Medical Center"},{"orgOrder":0,"company":"Aga Khan University","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"PAKISTAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Polio Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Aga Khan University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aga Khan University \/ World Health Organization","highestDevelopmentStatusID":"11","companyTruncated":"Aga Khan University \/ World Health Organization"},{"orgOrder":0,"company":"MSP Starch Products Inc.","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Potato Starch","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"MSP Starch Products Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSP Starch Products Inc. \/ Nutrasource","highestDevelopmentStatusID":"11","companyTruncated":"MSP Starch Products Inc. \/ Nutrasource"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Avita Medical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Recell","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Wake Forest University Health Sciences \/ Avita Medical","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ Avita Medical"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Jiangsu Province Centers for Disease Control and Prevention | Anhui Provincial Center for Disease Control and Prevention | Sichuan Center for Disease Control and Prevention | Beijing Institute of Biological Products Co Ltd. | Chengdu Institute of Biologic","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Sabin Inactivated Poliovirus Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China National Biotec Group \/ Jiangsu Province Centers for Disease Control and Prevention | Anhui Provincial Center for Disease Control and Prevention | Sichuan Center for Disease Control and Prevention | Beijing Institute of Biological Products Co Ltd. | Chengdu Institute of Biologic","highestDevelopmentStatusID":"11","companyTruncated":"China National Biotec Group \/ Jiangsu Province Centers for Disease Control and Prevention | Anhui Provincial Center for Disease Control and Prevention | Sichuan Center for Disease Control and Prevention | Beijing Institute of Biological Products Co Ltd. | Chengdu Institute of Biologic"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Shaanxi Provincial Center for Disease Control and Prevention | Hubei Provincial Center for Disease Control and Prevention | Beijing Institute of Biological Products Co Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"sIPV\/DTaP\/HepA Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China National Biotec Group \/ Shaanxi Provincial Center for Disease Control and Prevention | Hubei Provincial Center for Disease Control and Prevention | Beijing Institute of Biological Products Co Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"China National Biotec Group \/ Shaanxi Provincial Center for Disease Control and Prevention | Hubei Provincial Center for Disease Control and Prevention | Beijing Institute of Biological Products Co Ltd."},{"orgOrder":0,"company":"Prenetics Global","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Superfood","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Prenetics Global","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prenetics Global \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Prenetics Global \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Resilience Biosciences Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Traditional Gastrointestinal Remedy","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of British Columbia \/ Resilience Biosciences Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of British Columbia \/ Resilience Biosciences Inc"},{"orgOrder":0,"company":"Fudan University","sponsor":"LinkDoc Technology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Trametes Robiniophila Murr Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Granules","sponsorNew":"Fudan University \/ LinkDoc Technology","highestDevelopmentStatusID":"11","companyTruncated":"Fudan University \/ LinkDoc Technology"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Vaway","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Baylor Research Institute","sponsor":"Baylor Scott and White Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baylor Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor Research Institute \/ Baylor Scott and White Health","highestDevelopmentStatusID":"11","companyTruncated":"Baylor Research Institute \/ Baylor Scott and White Health"},{"orgOrder":0,"company":"Kim's Eye Hospital","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Kim's Eye Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kim's Eye Hospital \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Kim's Eye Hospital \/ Bayer AG"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nicorandil","moa":"vasodilators (undefined group)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ruijin Hospital \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Ruijin Hospital \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"Vasopressin receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"Total Definer Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Total Definer Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Total Definer Research Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Total Definer Research Group \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
Onabotulinumtoxina is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Mizoribine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Mizoribine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Plerixafor is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Sodium Chloride is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Dexmedetomidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Haloperidol is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of unspecified medical condition.
Details :
BCG Vaccine is a Vaccine drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of unspecified medical condition.
Details :
Bremelanotide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Gadopiclenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Contrast Enhanced Imaging.
Reset All
